Designing and development of epitope-based vaccines against Helicobacter pylori. (4th July 2022)

• Record Type: Journal Article
• Authors: Mohammadzadeh, Roghayeh; Soleimanpour, Saman; Pishdadian, Abbas; Farsiani, Hadi
• Is Part Of: Critical reviews in microbiology. Volume 48:Number 4(2022)
• Page Start: 489
• Page End: 512
• Publication Date: 2022-07-04
• Subjects: Helicobacter pylori -- epitope-based vaccines -- epitopes -- built-in adjuvants -- bioinformatic tools; Microbiology -- Periodicals; Microbiology -- Periodicals; Review Literature -- Periodicals; 579
• DOI: 10.1080/1040841X.2021.1979934
• Languages: English
• ISSNs: 1040-841X

Abstract

Abstract: Helicobacter pylori infection is the principal cause of serious diseases (e.g. gastric cancer and peptic ulcers). Antibiotic therapy is an inadequate strategy in H. pylori eradication because of which vaccination is an inevitable approach. Despite the presence of countless vaccine candidates, current vaccines in clinical trials have performed with poor efficacy which makes vaccination extremely challenging. Remarkable advancements in immunology and pathogenic biology have provided an appropriate opportunity to develop various epitope-based vaccines. The fusion of proper antigens involved in different aspects of H. pylori colonization and pathogenesis as well as peptide linkers and built-in adjuvants results in producing epitope-based vaccines with excellent therapeutic efficacy and negligible adverse effects. Difficulties of the in vitro culture of H. pylori, high genetic variation, and unfavourable immune responses against feeble epitopes in the complete antigen are major drawbacks of current vaccine strategies that epitope-based vaccines may overcome. Besides decreasing the biohazard risk, designing precise formulations, saving time and cost, and induction of maximum immunity with minimum adverse effects are the advantages of epitope-based vaccines. The present article is a comprehensive review of strategies for designing and developing epitope-based vaccines to provide insights into the innovative vaccination against H. pylori .